An MRI Rating Scale for Amyloid-Related Imaging Abnormalities with Edema or Effusion

REFERENCES

1. 1.↵
   1. McKhann G,
   2. Drachman D,
   3. Folstein M,
   4. et al

   . Clinical diagnosis of Alzheimer's disease: a report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939–44

   CrossRefPubMed
2. 2.↵
   1. Selkoe DJ,
   2. Schenk D

   . Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003;43:545–84

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Schenk D,
   2. Barbour R,
   3. Dunn W,
   4. et al

   . Immunization with amyloid-beta attenuated Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173–77

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Gilman S,
   2. Koller M,
   3. Black RS,
   4. et al

   . Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553–62

   CrossRefPubMed
5. 5.↵
   1. Salloway S,
   2. Sperling R,
   3. Gilman S,
   4. et al

   . A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061–70

   CrossRef
6. 6.↵
   1. Ostrowitzki S,
   2. Deptula D,
   3. Thurfjell L,
   4. et al

   . Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012;69:198–207

   CrossRefPubMed
7. 7.↵
   1. Weiner HL,
   2. Frenkel D

   . Immunology and immunotherapy of Alzheimer's disease. Nat Rev Immunol 2006;6:404–16

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Rinne JO,
   2. Brooks DJ,
   3. Rossor MN,
   4. et al

   . 11C-PIB assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending dose study. Lancet Neurol 2010;9:363–72

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Bayer AJ,
   2. Bullock R,
   3. Jones RW,
   4. et al

   . Evaluation of the safety and immunogenecity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005;64:94–101

   CrossRef
10. 10.↵
    1. Sperling R,
    2. Salloway S,
    3. Brooks DJ,
    4. et al

    . Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 2012;11:241–49

    CrossRefPubMed
11. 11.↵
    1. Nicoll JA,
    2. Wilkinson D,
    3. Holmes C,
    4. et al

    . Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003;9:448–52

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Boche D,
    2. Zotova E,
    3. Weller RO,
    4. et al

    . Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 2008;131:3299–310

    Abstract/FREE Full Text
13. 13.↵
    1. Black RS,
    2. Sperling RA,
    3. Safirstein B,
    4. et al

    . A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2010;24:198–203

    CrossRefPubMed
14. 14.↵
    1. Cordonnier C,
    2. van der Flier WM

    . Brain microbleeds and Alzheimer's disease: innocent observation or key player? Brain 2011;134:335–44

    Abstract/FREE Full Text
15. 15.↵
    1. Greenberg SM,
    2. Vernooij MW,
    3. Cordonnier C,
    4. et al

    . Cerebral microbleeds: a guide to detection and interpretation. Lancet Neurol 2009;8:165–74

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Sperling RA,
    2. Jack CR,
    3. Black SE,
    4. et al

    . Amyloid-related abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Round Table Workgroup. Alzheimers Dement 2011;7:367–85

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Gregoire SM,
    2. Chaudhary UJ,
    3. Brown MM,
    4. et al

    . The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. Neurology 2009;73:1759–66

    CrossRef
18. 18.↵
    1. Wahlund LO,
    2. Barkhof F,
    3. Fazekas F,
    4. et al

    . A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001;32:1318–22

    Abstract/FREE Full Text
19. 19.↵
    1. McGraw KO,
    2. Wong SP

    . Forming inferences about some intraclass correlation coefficients. Psychological Methods 1996;1:30–46

    CrossRefWeb of Science
20. 20.↵
    1. Bartko JJ

    . The intraclass correlation coefficient as a measure of reliability. Psychological Reports 1966;19:3–11

    CrossRefPubMedWeb of Science